Australia - English SELECT A COUNTRY

MEETING PATIENTS’ NEEDS

focusimg1_03

Our focus is the provision of life-changing products to patients who need them most. Our discovery and development efforts are focused on a core set of therapeutic areas where we have proven expertise and where we believe we can have an even greater impact on the disease and how it is managed. These core areas of focus include immunology, liver disease, neuroscience and oncology.


IMMUNOLOGy

As leading experts in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases in the field of immunology, including rheumatology and dermatology. AbbVie is investigating several diseases which have few or no treatments, including uveitis, hidradenitis suppurativa, osteoarthritis and lupus. In addition, we are progressing next-generation therapies in rheumatoid arthritis with the objective to improve the current standard of care.


LIVER DISEASE

Our antiviral program focuses on the development of treatments for chronic hepatitis C virus (HCV), a liver disease that affects more than 160 million people worldwide including 230,000 Australians.1 HCV infections potentially lead to long-term complications and chronic liver disease. We are committed to advancing science while finding the best treatment options for patients.


NEUROSCIENCE

Our current innovative research focuses on compounds that have the potential to treat a variety of chronic disabling neurological conditions including Parkinson’s disease, the second most common degenerative neurological disease in Australia.2


Oncology

Our research is committed to discovering and developing targeted therapies that work against the processes cancer cells need to survive. AbbVie’s oncology pipeline includes multiple new molecules in clinical trials being studied in more than 15 cancers and tumour types, including some of the most widespread and difficult-to-treat, such as multiple myeloma and chronic lymphocytic leukaemia.


REFERENCES

  1. Australian Government. Dept of Health. Fourth National Hepatitis C Strategy 2014-17. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/A68444CDED77B3A9CA257BF0001CFD80/$File/Hep-C-Strategy2014-v3.pdf

  2. Parkinson’s Australia Information Sheet – Description, Incidence and Theories of Causation http://www.parkinsons.org.au/information_sheets Last accessed on 16 September 2015

Leave abbvie.com.au

The AbbVie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The AbbVie Internet site that you have requested may be in a language that differs from your country of origin.

The AbbVie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this AbbVie site?

Exit abbvie.com.au

The product-specific Internet site that you have requested is intended for the residents of Australia. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The product-specific Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this product-specific site?